All 37 were wild type for BRAF, NRAS, and NF1 genomic alterations (“triple wild-type”) (Fig. 2b), representing 2.0% of triple wild-type melanomas overall (37/1882) and showing significant enrichment for the triple wild-type subcategory compared with the melanoma cohort overall (p < 0.0001, Fisher’s exact test). This evidence concerns the gene NF1 and melanoma.